Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021
February 05, 2021 08:13 ET
|
Isoray, Inc.
RICHLAND, Wash., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Isoray Announces Pricing of $45 Million Public Offering
February 04, 2021 08:30 ET
|
Isoray, Inc.
RICHLAND, Wash., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
Isoray Announces Proposed Underwritten Public Offering
February 03, 2021 16:01 ET
|
Isoray, Inc.
RICHLAND, Wash., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding...
Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference
January 07, 2021 08:13 ET
|
Isoray, Inc.
RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout...
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
January 05, 2021 16:55 ET
|
Isoray, Inc.
HOUSTON, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k)...
Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRO
November 24, 2020 08:13 ET
|
Isoray, Inc.
RICHLAND, Wash., Nov. 24, 2020 (GLOBE NEWSWIRE) -- The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain cancers was underscored in multiple presentations...
Isoray Announces First Quarter Fiscal 2021 Financial Results
November 10, 2020 16:05 ET
|
Isoray, Inc.
Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, Wash., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical...
Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020
November 02, 2020 08:13 ET
|
Isoray, Inc.
RICHLAND, Wash., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference...
Isoray, Inc. Announces Pricing of $9.5 Million Public Offering
October 20, 2020 09:00 ET
|
Isoray, Inc.
RICHLAND, Wash., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
Isoray, Inc. Announces Proposed Underwritten Public Offering
October 19, 2020 16:56 ET
|
Isoray, Inc.
RICHLAND, Wash., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding...